Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients

BACKGROUND AND AIMS: Chronic hepatitis C (HCV) is a liver disease affecting over 3 million Americans. Liver biopsy is the gold standard for assessing liver fibrosis and is used as a benchmark for initiating treatment, though it is expensive and carries risks of complications. FibroTest is a non-inva...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shan, Schwarzinger, Michaël, Carrat, Fabrice, Goldhaber-Fiebert, Jeremy D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229483/
https://www.ncbi.nlm.nih.gov/pubmed/22164204
http://dx.doi.org/10.1371/journal.pone.0026783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229483/
https://www.ncbi.nlm.nih.gov/pubmed/22164204
http://dx.doi.org/10.1371/journal.pone.0026783

Ejemplares similares